New England Biolabs and Synthetic Genomics have inked a licensing deal that will allow NEB to market a master mix based on Gibson Assembly technology for molecular and synthetic biology applications, the companies said this week.

The Gibson Assembly master mix was developed by Daniel Gibson and colleagues at the J. Craig Venter Institute as part of a program sponsored by La Jolla, Calif.-based Synthetic Genomics. Introduced in 2009, the method uses a one-step, isothermal approach to enable the rapid assembly of multiple DNA fragments.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.